Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Leukemia·2026

Same author

Molecular diagnostics in cancer patients with suspected respiratory mold infections.

Journal of clinical microbiology·2025

Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Real-world analysis of teclistamab in 123 RRMM patients from Germany.

Leukemia·2024

Same author

Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma.

Annals of hematology·2023

Same author

Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing.

Blood advances·2022

Search research articles

Related Experiment Video

Updated: Nov 7, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

[CAR T-cell therapy for multiple myeloma].

X Zhou¹, H Einsele², S Danhof²

¹Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Deutschland. zhou_x@ukw.de.

|May 4, 2021

Summary

Chimeric antigen receptor (CAR) T-cell therapy shows promise for multiple myeloma (MM). Despite efficacy, challenges like relapse, severe side effects, and cost need addressing for standard care integration.

Keywords:

B‑cell maturation antigen CAR T‑cell therapy/adverse events Immunotherapy, adoptive Receptors, chimeric antigen T‑lymphocytes

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Nov 7, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Immunotherapy
Oncology
Hematology

Background:

Chimeric antigen receptor (CAR) T-cell therapy is an emerging immunotherapy.
It utilizes a patient's T-cells engineered to target cancer cells.
This approach is being investigated for multiple myeloma (MM).

Purpose of the Study:

To review the efficacy and safety of CAR T-cell therapy in MM.
To discuss the challenges and future directions of this treatment modality.

Main Methods:

Review of clinical trial data on CAR T-cell therapy for MM.
Analysis of B-cell maturation antigen (BCMA)-targeted CAR T-cells.

Main Results:

BCMA-targeted CAR T-cells demonstrate significant efficacy in MM patients.
High rates of relapse post-therapy are observed.
Severe adverse events, including cytokine release syndrome and neurotoxicity, can occur.

Conclusions:

CAR T-cell therapy is a promising treatment for MM with potential for standard care.
Further optimization is needed to address relapse, toxicity, and cost-benefit ratio.